CDRE · XBRL financial data

Cadre Holdings financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (CDRE's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	427,288	457,837	482,532	567,561	610,308
Cost of goods and services sold	256,598	282,159	281,806	334,080	350,680
Gross profit	170,690	175,678	200,726	233,481	259,628
Research and development	6,460	7,086	6,954	8,380	11,396
Selling, general and administrative	114,962	153,288	140,519	158,323	183,128
Total operating expenses	118,971	158,962	144,207	166,720	192,277
Operating income (loss)	51,719	16,716	56,519	66,761	67,351
Interest expense	16,425	6,206	4,531	7,822	—
Other income (expense)	(947)	(1,137)	936	(4,721)	7,455
Income tax expense (benefit)	6,531	3,553	14,283	18,085	18,187
Net income (loss)	12,661	5,820	38,641	36,133	44,139
Earnings per share, basic USD per share	0.44	0.16	1.03	0.90	1.08
Earnings per share, diluted USD per share	0.44	0.16	1.02	0.90	1.02
Weighted average shares, basic thousands of shares	28,599	36,110	37,534	39,946	40,867
Weighted average shares, diluted thousands of shares	28,599	36,122	37,920	40,332	43,433

Fiscal years (CDRE's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	33,857	45,286	87,691	124,933	122,898
Accounts receivable	48,344	64,557	58,360	93,523	110,607
Inventory	63,978	70,273	80,976	82,351	100,263
Total current assets	159,981	197,018	245,843	327,571	365,866
Property and equipment, net	33,053	45,285	44,647	45,243	78,822
Right-of-use asset	—	8,489	6,554	15,454	19,778
Goodwill	66,262	81,576	81,667	148,157	181,406
Total assets	311,796	391,952	431,179	652,713	770,031
Accounts payable	19,328	23,406	28,418	29,644	22,325
Accrued liabilities	40,736	38,720	44,524	46,413	61,066
Current portion of long-term debt	13,174	12,211	12,320	11,375	16,266
Total current liabilities	74,621	78,921	95,206	94,125	104,495
Total deposits	7,593	10,142	9,757	10,002	32,462
Long-term debt	146,516	137,476	127,812	211,830	290,987
Lease liability, non-current	—	4,965	3,186	10,733	15,039
Total liabilities	223,156	226,062	234,017	341,198	452,227
Retained earnings (accumulated deficit)	(37,052)	(42,741)	(16,106)	6,079	34,770
Total stockholders' equity	88,640	165,890	197,162	311,515	317,804
Total liabilities and equity	311,796	391,952	431,179	652,713	770,031
Common shares outstanding (cover page) thousands of shares	34,383	34,782	37,587	40,608	42,727

Fiscal years (CDRE's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	12,661	5,820	38,641	36,133	44,139
Stock-based compensation	355	31,858	9,368	8,369	12,239
Depreciation and amortization	13,718	15,651	15,737	16,420	18,633
Net cash from operating activities	40,094	46,409	73,209	31,777	63,705
Purchases of property and equipment	2,832	4,494	6,727	5,668	6,856
Net cash from investing activities	(2,832)	(59,626)	(6,520)	(147,426)	(96,369)
Proceeds from issuing common stock	—	56,329	—	91,776	—
Dividends paid	12,751	11,509	12,006	13,948	15,448
Net cash from financing activities	(6,596)	24,463	(24,722)	152,667	31,586
Net change in cash	30,984	11,429	42,405	37,242	394

SIC 3842 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3842 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Cadre Holdings	53,984	207,126	22,131*	42.8M	—	Q2 FY26 10-QJun 30, 2026
Avanos Medical	65,600	182,200	(12,300)	46.8M	5.3 quarters	Q1 FY26 10-QMar 31, 2026
Kestra Medical Technologies	68,558	30,971	(32,295)	59.6M	4.9 quarters	Q1 FY26 10-QJul 31, 2026
Beta Bionics	81,551	35,505	(12,287)*	54.4M	13.0 quarters	Q3 FY26 10-QSep 30, 2026
Iradimed	63,288	24,203	6,997*	12.8M	—	Q3 FY26 10-QSep 30, 2026
Mimedx Group	120,791	62,283	3,919*	145.9M	—	Q3 FY26 10-QSep 30, 2026
Embecta	214,700	271,700	41,800*	56.7M	—	Q3 FY26 10-QJun 30, 2026
Orthofix Medical	103,810	210,933	(6,224)*	40.7M	16.7 quarters	Q2 FY26 10-QJun 30, 2026
Angiodynamics	33,973	80,915	(15,330)	42.1M	2.2 quarters	Q1 FY27 10-QAug 31, 2026

Not investment advice. Not affiliated with the U.S. SEC.